Secondary Somatic Mutations Restoring<i>BRCA1/2</i>Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Secondary somatic mutations that restore BRCA1/2 in carcinomas from women with germline BRCA1/2 mutations predict resistance to platinum chemotherapy and may also predict resistance to PARP inhibitors. These mutations were detectable only in ovarian carcinomas of women whom have had previous chemotherapy, either for ovarian or breast carcinoma.